Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers

Charles G. Drake, MD, PhD
Published: Thursday, Feb 23, 2017



Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

Combinations of chemotherapy and immunotherapy are showing promise in bladder cancer, where traditional chemotherapy regimens are given upfront with immunotherapy. Drake predicts higher response rates and increased progression-free survival, but questions on overall survival remain.

Another combination that is potentially exciting, says Drake, is pairing hormonal therapy with immunotherapy in prostate cancer. Trials were conducted in patients before surgery, where immunotherapy seemed to be an effective addition to hormonal therapy.
 


Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

Combinations of chemotherapy and immunotherapy are showing promise in bladder cancer, where traditional chemotherapy regimens are given upfront with immunotherapy. Drake predicts higher response rates and increased progression-free survival, but questions on overall survival remain.

Another combination that is potentially exciting, says Drake, is pairing hormonal therapy with immunotherapy in prostate cancer. Trials were conducted in patients before surgery, where immunotherapy seemed to be an effective addition to hormonal therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Publication Bottom Border
Border Publication
x